Update on the management of cirrhosis - Focus on cost-effective preventative strategies

ClinicoEconomics and Outcomes Research

Volumn 5, Issue 1, 2013, Pages 143-152

  Neff, Guy W ^a   Kemmer, Nyingi ^a   Duncan, Christopher ^b   Alsina, Angel ^a  

^a Tampa General Medical Group   (United States)

^b Highline Gastroenterology   (United States)

Author keywords

Cost; Hepatic encephalopathy; Lactulose; Maintenance of remission; Rifaximin

Indexed keywords

ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CEFOTAXIME; CEPHALOSPORIN; CIPROFLOXACIN; DISACCHARIDE; LACTITOL; LACTULOSE; NEOMYCIN; OFLOXACIN; PLACEBO; RIFAXIMIN;

BACTERIAL PERITONITIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DIARRHEA; DISEASE ASSOCIATION; DRUG COST; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENDOSCOPIC VARICEAL LIGATION; ESOPHAGEAL VARICEAL BLEEDING; ESOPHAGUS DISEASE; FLATULENCE; HEPATIC ENCEPHALOPATHY; HOSPITAL COST; HUMAN; INFECTION PREVENTION; INTERMETHOD COMPARISON; LIVER CIRRHOSIS; LIVER PROTECTION; MAINTENANCE THERAPY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PORTAL HYPERTENSION; QUALITY OF LIFE; REVIEW; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; TREATMENT PLANNING; VEIN LIGATION;

EID: 84876197088     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S30675     Document Type: Review

References (71)

1. Heidelbaugh JJ, Bruderly M. Cirrhosis and chronic liver failure: part I. Diagnosis and evaluation. Am Fam Physician. 2006;74(5):756-762.
2. Garcia-Tsao G, Lim JK. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am J Gastroenterol. 2009;104(7):1802-1829.
3. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371(9615):838-851.
4. Cardenas A, Gines P. Management of complications of cirrhosis in patients awaiting liver transplantation. J Hepatol. 2005;42(Suppl 1):S124-S133.
5. Lim YS, Kim WR. The global impact of hepatic fibrosis and end-stage liver disease. Clin Liver Dis. 2008;12(4):733-746, vii.
6. Wasley A, Grytdal S, Gallagher K; Centers for Disease Control and Prevention. Surveillance for acute viral hepatitis-United States, 2006. MMWR Surveill Summ. 2008;57(2):1-24.
7. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29(Suppl 1):74-81.
8. Pyenson B, Fitch K, Iwasaki K. Consequences of Hepatitis C Virus (HCV): Costs of a Baby Boomer Epidemic of Liver Disease. New York, NY: Milliman, Inc; 2009. Available from: http://publications.milliman.com/research/health-rr/pdfs/consequences-hepatitis-c-virus-RR05-18-09.pdf. Accessed January 18, 2011.
9. Lecuyer A, Levy C, Gaudelus J, et al. Hospitalization of newborns and young infants for chickenpox in France. Eur J Pediatr. 2010;169(10):1293-1297.
10. Vrolijk JM, de Knegt RJ, Veldt BJ, Orlent H, Schalm SW. The treatment of hepatitis C: history, presence and future. Neth J Med. 2004;62(3):76-82.
11. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology. 2006;130(1):231-264.
12. Shepherd J, Waugh N, Hewitson P. Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review. Health Technol Assess. 2000;4(33):1-67.
13. Shiffman ML, Esteban R. Triple therapy for HCV genotype 1infection: telaprevir or boceprevir? Liver Int. 2012;32(Suppl 1):54-60.
14. McQueen C. FDA approves Vertex's new drug Incivek for treatment of hepatitis C [webpage on the Internet]. Princeton, NJ: The AIDS Beacon; May 23, 2011. Available from: http://www.aidsbeacon.com/news/2011/05/23/fda-approves-vertexs-new-drug-incivek-telaprevir-for-treatment-of-hepatitis-c/. Accessed January 21, 2013.
15. Brown RE, De Cock E, Colin X, Antonanzas F, Iloeje UH. Hepatitis Bmanagement costs in France, Italy, Spain, and the United Kingdom. J Clin Gastroenterol. 2004;38(10 Suppl 3):S169-S174.
16. Deniz B, Brogan AJ, Miller JD, Talbird SE, Thompson JR. Projections using decision-analytic modeling of long-term clinical value of telaprevir for the treatment of HCV patients who had failed prior peginterferon/ribavirin treatment [abstract]. Hepatology. 2011;54(S1):802A-803A.
17. Camma C, Petta S, Enea M, et al. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology. 2012;56(3):850-860.
18. Chhatwal J, Ferrante SA, Dasbach EJ, et al. Cost-effectiveness of boceprevir use in patients with chronic hepatitis C genotype-1 who failed prior treatment with peginterferon/ribavirin [abstract]. Hepatology. 2011;54(Suppl 1):801A-802A.
19. Ferrante SA, Chhatwal J, Elbasha E, et al. Cost-effectiveness of boceprevir based regimens in previously untreated adult subjects with chronic hepatitis C genotype 1 [abstract]. Hepatology. 2011;54(Suppl 1):795A-796A.
20. Grewal P, Martin P. Care of the cirrhotic patient. Clin Liver Dis. 2009;13(2):331-340.
21. Arguedas MR, Heudebert GR, Eloubeidi MA, Abrams GA, Fallon MB. Cost-effectiveness of screening, surveillance, and primary prophylaxis strategies for esophageal varices. Am J Gastroenterol. 2002;97(9):2441-2452.
22. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007;46(3):922-938.
23. Teran JC, Imperiale TF, Mullen KD, Tavill AS, McCullough AJ. Primary prophylaxis of variceal bleeding in cirrhosis: a cost-effectiveness analysis. Gastroenterology. 1997;112(2):473-482.
24. Saab S, DeRosa V, Nieto J, Durazo F, Han S, Roth B. Costs and clinical outcomes of primary prophylaxis of variceal bleeding in patients with hepatic cirrhosis: a decision analytic model. Am J Gastroenterol. 2003;98(4):763-770.
25. D'Amico G, Pietrosi G, Tarantino I, Pagliaro L. Emergency sclerotherapy versus medical interventions for bleeding oesophageal varices in cirrhotic patients. Cochrane Database Syst Rev. 2002;1:CD002233.
26. O'Donnell TF Jr, Gembarowicz RM, Callow AD, Pauker SG, Kelly JJ, Deterling RA. The economic impact of acute variceal bleeding: cost-effectiveness implications for medical and surgical therapy. Surgery. 1980;88(5):693-701.
27. Rubenstein JH, Eisen GM, Inadomi JM. A cost-utility analysis of secondary prophylaxis for variceal hemorrhage. Am J Gastroenterol. 2004;99(7):1274-1288.
28. Russo MW, Zacks SL, Sandler RS, Brown RS. Cost-effectiveness analysis of transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic therapy for the prevention of recurrent esophageal variceal bleeding. Hepatology. 2000;31(2):358-363.
29. Ribeiro TC, Chebli JM, Kondo M, Gaburri PD, Chebli LA, Feldner AC. Spontaneous bacterial peritonitis: how to deal with this life-threatening cirrhosis complication? Ther Clin Risk Manag. 2008;4(5):919-925.
30. Das A. A cost analysis of long term antibiotic prophylaxis for spontaneous bacterial peritonitis in cirrhosis. Am J Gastroenterol. 1998;93(10):1895-1900.
31. Sabat M, Kolle L, Soriano G, et al. Parenteral antibiotic prophylaxis of bacterial infections does not improve cost-efficacy of oral norfloxacin in cirrhotic patients with gastrointestinal bleeding. Am J Gastroenterol. 1998;93(12):2457-2462.
32. Loomba R, Wesley R, Bain A, Csako G, Pucino F. Role of fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis: meta-analysis. Clin Gastroenterol Hepatol. 2009;7(4):487-493.
33. Fernandez J, Ruiz del Arbol L, Gomez C, et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology. 2006;131(4):1049-1056.
34. Soriano G, Guarner C, Tomas A, et al. Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. Gastroenterology. 1992;103(4):1267-1272.
35. Dupeyron C, Mangeney N, Sedrati L, Campillo B, Fouet P, Leluan G. Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis. Antimicrob Agents Chemother. 1994;38(2):340-344.
36. Umgelter A, Reindl W, Miedaner M, Schmid RM, Huber W. Failure of current antibiotic first-line regimens and mortality in hospitalized patients with spontaneous bacterial peritonitis. Infection. 2009;37(1):2-8.
37. Yakar T, Guclu M, Serin E, Aliskan H, Husamettin E. A recent evaluation of empirical cephalosporin treatment and antibiotic resistance of changing bacterial profiles in spontaneous bacterial peritonitis. Dig Dis Sci. 2010;55(4):1149-1154.
38. Navasa M, Follo A, Llovet JM, et al. Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology. 1996;111(4):1011-1017.
39. Ricart E, Soriano G, Novella MT, et al. Amoxicillin-clavulanic acid versus cefotaxime in the therapy of bacterial infections in cirrhotic patients. J Hepatol. 2000;32(4):596-602.
40. Tuncer I, Topcu N, Durmus A, Turkdogan MK. Oral ciprofloxacin versus intravenous cefotaxime and ceftriaxone in the treatment of spontaneous bacterial peritonitis. Hepatogastroenterology. 2003;50(53):1426-1430.
41. Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341(6):403-409.
42. Poordad FF. The burden of hepatic encephalopathy. Aliment Pharmacol Ther. 2007;25(Suppl 1):3-9.
43. Gerber T, Schomerus H. Hepatic encephalopathy in liver cirrhosis: pathogenesis, diagnosis and management. Drugs. 2000;60(6):1353-1370.
44. Hartmann IJ, Groeneweg M, Quero JC, et al. The prognostic significance of subclinical hepatic encephalopathy. Am J Gastroenterol. 2000;95(8):2029-2034.
45. Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ. 2004;328(7447):1046.
46. Paik YH, Lee KS, Han KH, et al. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J. 2005;46(3):399-407.
47. Poo JL, Gongora J, Sanchez-Avila F, et al. Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study. Ann Hepatol. 2006;5(4):281-288.
48. Sharma P, Agrawal A, Sharma BC, Sarin SK. Prophylaxis of hepatic encephalopathy in acute variceal bleed: a randomized controlled trial of lactulose versus no lactulose. J Gastroenterol Hepatol. 2011;26(6):996-1003.
49. Sharma BC, Sharma P, Agrawal A, Sarin SK. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology. 2009;137(3):885-891.
50. Leevy CB, Phillips JA. Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci. 2007;52(3):737-741.
51. Abou-Assi S, Vlahcevic ZR. Hepatic encephalopathy. Metabolic consequence of cirrhosis often is reversible. Postgrad Med. 2001;109(2):52-54.
52. Atterbury CE, Maddrey WC, Conn HO. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled, double-blind clinical trial. Am J Dig Dis. 1978;23(5):398-406.
53. Blanc P, Daures JP, Liautard J, et al. [Lactulose-neomycin combination versus placebo in the treatment of acute hepatic encephalopathy. Results of a randomized controlled trial]. Gastroenterol Clin Biol. 1994;18(12):1063-1068. French.
54. Conn HO, Leevy CM, Vlahcevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology. 1977;72(4 Pt 1):573-583.
55. Dawson AM, McLaren J, Sherlock S. Neomycin in the treatment of hepatic coma. Lancet. 1957;273(7008):1262-1268.
56. Rothenberg ME, Keeffe EB. Antibiotics in the management of hepatic encephalopathy: an evidence-based review. Rev Gastroenterol Disord. 2005;5(Suppl 3):26-35.
57. Strauss E, Tramote R, Silva EP, et al. Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatogastroenterology. 1992;39(6):542-545.
58. Sidhu SS, Goyal O, Mishra BP, Sood A, Chhina RS, Soni RK. Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). Am J Gastroenterol. 2011;106(2):307-316.
59. Bucci L, Palmieri GC. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin. 1993;13(2):109-118.
60. Festi D, Mazzella G, Orsini M, et al. Rifaximin in the treatment of chronic hepatic encephalopathy: results of a multicenter study of efficacy and safety. Curr Ther Res. 1993;54(5):598-609.
61. Giacomo F, Francesco A, Michele N, Oronzo S, Antonella F. Rifaximin in the treatment of hepatic encephalopathy. Eur J Clin Res. 1993;4:57-66.
62. Loguercio C, Federico A, De Girolamo V, Ferrieri A, Del Vecchio Blanco C. Cyclic treatment of chronic hepatic encephalopathy with rifaximin. Results of a double-blind clinical study. Minerva Gastroenterol Dietol. 2003;49(1):53-62.
63. Mas A, Rodes J, Sunyer L, et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol. 2003;38(1):51-58.
64. Massa P, Vallerino E, Dodero M. Treatment of hepatic encephalopathy with rifaximin: double-blind, double dummy study versus lactulose. Eur J Clin Res. 1993;4:7-18.
65. Huang E, Esrailian E, Spiegel BM. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy-a decision analysis. Aliment Pharmacol Ther. 2007;26(8):1147-1161.
66. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071-1081.
67. Leevy CB. Economic impact of treatment options for hepatic encephalopathy. Semin Liver Dis. 2007;27(Suppl 2):26-31.
68. Neff GW, Kemmer N, Zacharias VC, et al. Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy. Transplant Proc. 2006;38(10):3552-3555.
69. Neff GW, Kemmer N, Parkinson E, et al. Outcomes in length of hospital stay in cirrhotics admitted for overt hepatic encephalopathy [abstract]. Am Coll Gastroeneterol. 2012;107(Suppl):S601.
70. Neff GW, Kemmer N, Parkinson E, et al. Readmission rates and maintenance overt hepatic encephalopathy [abstract]. Am Coll Gastroeneterol. 2012;107(Suppl 1):S184-S185.
71. Healthcare Cost and Utilization Project. Agency for Healthcare Research and Quality, [homepage on the Internet]. http://hcupnet.ahrq.gov. Accessed June 20, 2012.